Allogeneic hematopoietic cell transplantation

Allogeneic hematopoietic cell transplantation has been studied in 11 papers since 2018: 10 observational studies in people, 1 review; 1 in the past year. Its furthest trials in people are at phase 3. The newest paper, Mar 28, 2026: “Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation”.

Intervention Phase 3

11 papers study it6 findingsUpdated Mar 28, 2026

See all 11

“recipients had longer mean telomere length 9 to 15 months post-transplant than they had pretransplant.”

Mononuclear Cell Telomere Attrition Is Associated with Overall Survival after Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic MalignanciesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018doi:10.1016/j.bbmt.2018.09.025

1 of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

5 independent labs in 4 countries
1 finding against
64 trials, none about aging, 4 with no results posted

Funders: Narodowe Centrum Nauki and others
2 of 6 findings with company ties

Humans10

What did studies of Allogeneic hematopoietic cell transplantation find?

Studies of Allogeneic hematopoietic cell transplantation measured 4 outcomes; the most studied are moderate cognitive impairment (1 study), clonal diversity (1) and telomere length (1).

Moderate cognitive impairment

upin humans1

1 study

Allogeneic hematopoietic cell transplantation increases moderate cognitive impairment in humans (nearly doubled).
“The prevalence of post-HCT mild impairment scores decreased, and moderate impairment scores nearly doubled.”
Humans3 months post-HCTn = 171
Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment
Journal of cancer survivorship : research and practiceJun 20, 2025

Clonal diversity

downin humans1

1 study

Allogeneic hematopoietic cell transplantation decreases clonal diversity in humans (equivalent to around 10-15 years of additional ageing).
“Recipients had lower clonal diversity than matched donors, equivalent to around 10-15 years of additional ageing, arising from up to 25-fold greater expansion of stem cell clones.”
Humans9-31 years after HLA-matched sibling HCTbone marrow
Clonal dynamics after allogeneic haematopoietic cell transplantation
NatureOct 30, 2024

Telomere length

downin humans1

1 study

Allogeneic hematopoietic cell transplantation decreases telomere length in humans (1.7 kb vs 2.1 kb, p = 0.02).
“Median telomeric length (TL) of CD8+ lymphocytes was significantly longer in donors compared to recipients (on average 2,1 kb and 1,7 kb respectively, p = 0,02).”
HumansCD8+ lymphocytes
Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors
Immunity & ageing : I & ANov 2, 2022

What is Allogeneic hematopoietic cell transplantation linked with?

Studies link Allogeneic hematopoietic cell transplantation with 2 measures, most often CD8+ lymphocyte telomere length (1 study) and telomere length (1).

CD8+ lymphocyte telomere length

downin humans1

1 study

Allogeneic hematopoietic cell transplantation is associated with CD8+ lymphocyte telomere length in humans (Donors 2.1 kb versus recipients 1.7 kb; p=0.02).
“Median telomeric length (TL) of CD8+ lymphocytes was significantly longer in donors compared to recipients”
Humansallo-HCT recipients compared with their respective donorsCD8+ lymphocyte
Ageing of long-term allogeneic hematopoietic cells recipients compared to their donors
Research SquareApr 21, 2022Preprint

Has Allogeneic hematopoietic cell transplantation been tested in people?

0 about aging, of 64

Yes: 10 observational studies in people have been published, and 64 trials are registered.

In trials

Leukemia myeloid acute
Phase 3Results posted24 trials
Precursor cell lymphoblastic leukemia lymphoma
Phase 3Active, not recruiting16 trials
Leukemia, Biphenotypic, Acute
Phase 3Active, not recruiting6 trials
Burkitt lymphoma
Phase 3Active, not recruiting4 trials
Precursor T-cell lymphoblastic leukemia/lymphoma
Phase 3Active, not recruiting2 trials
Leukemia
Phase 3Results posted1 trial

40 of 48

Readouts due

Apr 1, 2027
Itacitinib for the Prevention of Graft Versus Host Disease
Phase 2Active, not recruiting
Apr 12, 2027
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
Phase 1Active, not recruiting
Sep 2027
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
Phase 1Active, not recruiting

Stopped

NCT03870750TerminatedHematologic neoplasms
Study terminated due to meeting interim analysis futility endpoint. No difference was found between two treatment arms at interim analysis of primary outcome.
NCT03246906TerminatedMyelodysplastic syndrome
Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.
NCT04205240TerminatedMultiple myeloma
Poor accrual
NCT04530487TerminatedNeuroblastoma
PI Request
NCT03878199TerminatedEssential thrombocythemia
The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.